Chronic myeloid leukemia patients call for quality and consistency when generics are introduced to treat their cancer.
作者信息
Geissler J, Sharf G, Cugurovic J, Padua R, Narbutas Š, Remic M, Venkatesh V
机构信息
Leukemia Patient Advocates Foundation, Bern, Switzerland.
LeukaNET e.V., Riemerling, Germany.
出版信息
Leukemia. 2016 Dec;30(12):2396-2397. doi: 10.1038/leu.2016.220. Epub 2016 Aug 3.
Abstract
摘要
相似文献
1
Chronic myeloid leukemia patients call for quality and consistency when generics are introduced to treat their cancer.在引入仿制药治疗慢性髓性白血病患者的癌症时，患者需要质量和一致性。
Leukemia. 2016 Dec;30(12):2396-2397. doi: 10.1038/leu.2016.220. Epub 2016 Aug 3.
2
Persistence with generic imatinib for chronic myeloid leukemia: a matched cohort study.慢性髓性白血病使用通用型伊马替尼的持续性：一项匹配队列研究。
Haematologica. 2019 Jul;104(7):e293-e295. doi: 10.3324/haematol.2018.211235. Epub 2019 Jan 10.
3
What Happens When Imatinib Goes Generic?伊马替尼成为非专利药后会发生什么？
J Natl Compr Canc Netw. 2016 Feb;14(2):128-31. doi: 10.6004/jnccn.2016.0016.
4
Association of Generic Imatinib Availability and Pricing With Trends in Tyrosine Kinase Inhibitor Use in Patients With Chronic Myelogenous Leukemia.曲妥珠单抗仿制药的可及性和定价与慢性髓性白血病患者酪氨酸激酶抑制剂使用趋势的关系。
JAMA Oncol. 2020 Dec 1;6(12):1969-1971. doi: 10.1001/jamaoncol.2020.4660.
5
The Efficacy of Generic Imatinib as First- and Second-line Therapy: 3-Year Follow-up of Patients With Chronic Myeloid Leukemia.通用型伊马替尼作为一线和二线治疗的疗效：慢性髓性白血病患者的3年随访
Clin Lymphoma Myeloma Leuk. 2017 Apr;17(4):238-240. doi: 10.1016/j.clml.2017.02.001. Epub 2017 Feb 16.
6
Generic formulations of imatinib for treatment of Philadelphia chromosome-positive leukemia in pediatric patients.伊马替尼的仿制药治疗儿童费城染色体阳性白血病。
Pediatr Blood Cancer. 2018 Dec;65(12):e27431. doi: 10.1002/pbc.27431. Epub 2018 Aug 30.
7
Generic imatinib in the treatment of chronic myeloid leukemia: two years' experience in Latvia.通用型伊马替尼治疗慢性髓性白血病：拉脱维亚的两年经验。
Exp Oncol. 2017 Jul;39(2):151-154.
8
Generics in chronic myeloid leukemia: current arguments for and against and the established evidence.慢性髓性白血病中的仿制药：支持与反对的当前论据及既有证据
Expert Rev Hematol. 2014 Dec;7(6):697-9. doi: 10.1586/17474086.2014.966679. Epub 2014 Oct 8.
9
Current evidence on the efficacy and safety of generic imatinib in CML and the impact of generics on health care costs.目前关于通用伊马替尼在 CML 中的疗效和安全性的证据，以及仿制药对医疗保健成本的影响。
Blood Adv. 2021 Sep 14;5(17):3344-3353. doi: 10.1182/bloodadvances.2021004194.
10
The impact of new generic formulations of imatinib mesylate on general quality of life in chronic phase chronic myeloid leukaemia patients.甲磺酸伊马替尼新通用制剂对慢性期慢性髓性白血病患者总体生活质量的影响。
Eur J Cancer Care (Engl). 2017 Mar;26(2). doi: 10.1111/ecc.12423. Epub 2015 Nov 23.
引用本文的文献
1
Use of generic imatinib as first-line treatment in patients with chronic myeloid leukemia (CML): the GIMS (Glivec to Imatinib Switch) study.通用型伊马替尼用于慢性粒细胞白血病（CML）患者一线治疗：GIMS（格列卫至伊马替尼转换）研究
Blood Res. 2020 Sep 30;55(3):139-145. doi: 10.5045/br.2020.2020130.
2
Efficacy and safety of generic imatinib after switching from original imatinib in patients treated for chronic myeloid leukemia in the United States.美国接受治疗的慢性髓性白血病患者从原研伊马替尼换用通用伊马替尼的疗效和安全性。
Cancer Med. 2019 Nov;8(15):6559-6565. doi: 10.1002/cam4.2545. Epub 2019 Sep 10.
3
Persistence with generic imatinib for chronic myeloid leukemia: a matched cohort study.慢性髓性白血病使用通用型伊马替尼的持续性：一项匹配队列研究。
Haematologica. 2019 Jul;104(7):e293-e295. doi: 10.3324/haematol.2018.211235. Epub 2019 Jan 10.
本文引用的文献
1
Comparative study of the anti-leukemic effects of imatinib mesylate, Glivec™ tablet and its generic formulation, OHK9511.甲磺酸伊马替尼、格列卫™片剂及其仿制药OHK9511抗白血病作用的比较研究
Biol Pharm Bull. 2015;38(3):411-6. doi: 10.1248/bpb.b14-00652. Epub 2015 Jan 8.
2
Generic imatinib: the real-deal or just a deal?通用型伊马替尼：是真货还是徒有其名？
Leuk Lymphoma. 2014 Dec;55(12):2678-80. doi: 10.3109/10428194.2014.921299.
3
Clinical efficacy of generic imatinib.通用型伊马替尼的临床疗效。
J Oncol Pharm Pract. 2015 Feb;21(1):76-9. doi: 10.1177/1078155214522143. Epub 2014 Feb 21.
4
Report of chronic myeloid leukemia in chronic phase from Tata Memorial Hospital, Mumbai, 2002-2008.孟买塔塔纪念医院2002 - 2008年慢性期慢性髓性白血病报告。
Indian J Med Paediatr Oncol. 2013 Jul;34(3):164-7. doi: 10.4103/0971-5851.123716.
5
Clinical pharmacology of tyrosine kinase inhibitors becoming generic drugs: the regulatory perspective.酪氨酸激酶抑制剂成为仿制药的临床药理学：监管视角
J Exp Clin Cancer Res. 2014 Feb 7;33(1):15. doi: 10.1186/1756-9966-33-15.
6
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.欧洲白血病网络关于慢性髓性白血病管理的建议：2013 年版。
Blood. 2013 Aug 8;122(6):872-84. doi: 10.1182/blood-2013-05-501569. Epub 2013 Jun 26.
7
Hematologic Relapse after 2 Years on a Non-Authorized Copy Version of Imatinib in a Patient with Chronic Myeloid Leukemia in Chronic Phase: A Case Report.慢性期慢性髓性白血病患者使用伊马替尼盗版药2年后出现血液学复发：一例报告
Case Rep Oncol. 2010 Jul 26;3(2):272-276. doi: 10.1159/000319150.
8
Changing therapy from Glivecto a "copy" imatinib results in a worsening of chronic myeloid leukemia disease status: two case reports.从格列卫转换为“仿制”伊马替尼进行治疗会导致慢性髓性白血病疾病状态恶化：两例病例报告。
Cases J. 2009 Dec 17;2:9342. doi: 10.1186/1757-1626-2-9342.
9
Failure of copy Imatib (CIPLA, India) to maintain hematologic and cytogenetic responses in chronic myeloid leukemia in chronic phase.印度西普拉公司的伊马替尼（Imatib）仿制药无法维持慢性期慢性髓性白血病的血液学和细胞遗传学反应。
Int J Hematol. 2010 Jan;91(1):104-6. doi: 10.1007/s12185-009-0431-1.
10
Bioequivalence of two film-coated tablets of imatinib mesylate 400 mg: a randomized, open-label, single-dose, fasting, two-period, two-sequence crossover comparison in healthy male South American volunteers.甲磺酸伊马替尼 400 毫克两种薄膜片剂的生物等效性：在健康的南美男性志愿者中进行的随机、开放标签、单次、禁食、两周期、两序列交叉比较研究。
Clin Ther. 2009 Oct;31(10):2224-32. doi: 10.1016/j.clinthera.2009.10.009.
Zotero 插件